Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo

Trial Profile

Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solanezumab (Primary) ; Florbetapir F 18
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms EXPEDITION-2
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 30 Jul 2021 Results from ENGAGE, EMERGE, Expedition 1, 2, and 3 and the PRIME study; combining evidence across outcomes and trials using bayesian hierarchical analysis, presented at the Alzheimer's Association International Conference 2021
  • 31 Jul 2020 Results of post hoc analysis from EXPEDITION-1 and EXPEDITION-2 presented at the Alzheimer's Association International Conference 2020
  • 20 Jul 2017 Results of PK/PD model development and evaluation using patient data from NCT00905372, NCT00904683, NCT01900665 trials presented at the Alzheimer's Association International Conference 2017

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top